Stoke Therapeutics (STOK) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$248.3 million.
- Stoke Therapeutics' Enterprise Value fell 6543.96% to -$248.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.3 million, marking a year-over-year decrease of 6543.96%. This contributed to the annual value of -$216.9 million for FY2024, which is 769.88% down from last year.
- Stoke Therapeutics' Enterprise Value amounted to -$248.3 million in Q3 2025, which was down 6543.96% from -$247.7 million recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Enterprise Value ranged from a high of -$150.1 million in Q3 2024 and a low of -$357.3 million during Q1 2025
- For the 4-year period, Stoke Therapeutics' Enterprise Value averaged around -$236.3 million, with its median value being -$231.4 million (2023).
- As far as peak fluctuations go, Stoke Therapeutics' Enterprise Value soared by 3009.85% in 2024, and later plummeted by 10009.07% in 2025.
- Over the past 4 years, Stoke Therapeutics' Enterprise Value (Quarter) stood at -$229.6 million in 2022, then grew by 12.28% to -$201.4 million in 2023, then fell by 7.7% to -$216.9 million in 2024, then dropped by 14.48% to -$248.3 million in 2025.
- Its Enterprise Value stands at -$248.3 million for Q3 2025, versus -$247.7 million for Q2 2025 and -$357.3 million for Q1 2025.